Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis - PubMed
5 days ago
- #treatment efficacy
- #prostate cancer
- #network meta-analysis
- Triple and dual therapies for metastatic hormone-sensitive prostate cancer (mHSPC) were compared for efficacy and safety.
- Darolutamide + docetaxel + ADT showed the best overall survival (HR: 0.54; 95% CI: 0.39-0.76; P score = 0.89).
- Abiraterone + prednisolone + docetaxel + ADT was the best for progression-free survival (HR: 0.33; 95% CI: 0.19-0.53; P score = 0.92).
- Apalutamide + ADT had the lowest odds of adverse events.
- Triple therapies were highly effective but associated with significantly higher adverse events.